Developer · DFTX · United States
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) is a New York-based clinical-stage biopharmaceutical company developing psychedelic-inspired therapeutics for psychiatric and neurological disorders, led by DT120 (lysergide D-tartrate / LSD) for anxiety and depression. The company rebranded from MindMed in January 2026.
2compounds
5programs
5indications
Phase 3lead asset
Pipeline (2)
- Generalized anxiety disorderPhase 3Active
- Major depressive disorderPhase 3Recruiting
- Post-traumatic stress disorderPhase 3Active
- Attention-deficit/hyperactivity disorderDiscontinuedDiscontinued
- Autism spectrum disorderPhase 2Recruiting
Deals & partnerships
- Lysergide D-tartrate (MM120 / LSD)Licensor Catalent, Inc.
- Jun 25, 2026FinancingDefinium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 programClosed an underwritten public offering of 23,676,471 common shares at $34.00/share (including full exercise of the underwriters' 3,088,235-share option) for ~$805M gross / ~$758M net proceeds, upsized from a $500M proposed offering announced 2026-06-22 and priced at $700M/20,588,236 shares on 2026-06-23. Proceeds earmarked for R&D and DT120 ODT commercialization prep. Compound-wide corporate financing, not indication-specific.
- Aug 3, 2023Licensing dealCatalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)Catalent granted MindMed exclusive rights to its patented Zydis fast-dissolve orally disintegrating tablet (ODT) technology for all salt and polymorphic forms of lysergide for pharmaceutical use in the United States, United Kingdom, European Union, Switzerland, Israel, and Canada. The technology underpins the MM120 (now DT120) ODT formulation.
Catalysts · 2 upcoming · 1 reported
- 2026Anticipated
DT402forAutism spectrum disorderTopline data
Initial Phase 2a data for DT402 in autism spectrum disorder anticipated in 2026
- 2027Anticipated
Lysergide D-tartrate (MM120 / LSD)forPost-traumatic stress disorderRegistry results
Phase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027
Recently reported
- 2025-03-19missed
Lysergide D-tartrate (MM120 / LSD)forAttention-deficit/hyperactivity disorderFull results
Phase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145)
Recent activity
- Apr 22, 2026Phase changeLysergide D-tartrate (MM120 / LSD)·Post-traumatic stress disorderPhase 3Definium Therapeutics announced expansion of the DT120 ODT program into PTSD with the planned Phase 3 'Haven' study (~200 participants, 1:1 DT120 ODT vs placebo, primary endpoint CAPS-5 at Week 8), initiation expected in 2027. No NCT registered as of this record.source ↗
- Dec 3, 2025Phase changeDT402·Autism spectrum disorderPhase 2Phase 2a ASD study (NCT07303907) start date 2025-12-03; overall status RECRUITING. Company reported the trial was initiated in 4Q 2025.source ↗
- Sep 1, 2025Phase changeLysergide D-tartrate (MM120 / LSD)·Major depressive disorderPhase 3Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.source ↗
- Mar 19, 2025ReadoutLysergide D-tartrate (MM120 / LSD)·Attention-deficit/hyperactivity disordermissedPhase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145)source ↗
- Jan 29, 2025Phase changeLysergide D-tartrate (MM120 / LSD)·Generalized anxiety disorderPhase 3First patient dosed in Panorama (NCT06809595), second pivotal Phase 3 GAD study.source ↗
- Jan 1, 2025Phase changeDT402·Autism spectrum disorderPhase 1Single-ascending-dose Phase 1 study of DT402 in healthy adult volunteers completed; characterized safety, tolerability, PK and PD. No dose-limiting safety issues reported at doses up to ~255 mg (company commentary). Exact completion date not precisely disclosed in reviewed sources; anchored to 2025 with approximate day precision.source ↗
- Dec 11, 2024Phase changeLysergide D-tartrate (MM120 / LSD)·Generalized anxiety disorderPhase 3First patient dosed in Phase 3 Voyage (NCT06741228) — first-ever Phase 3 of LSD.source ↗
- Mar 7, 2024Phase changeLysergide D-tartrate (MM120 / LSD)·Generalized anxiety disorderPhase 2FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.source ↗
- Dec 4, 2023Phase changeLysergide D-tartrate (MM120 / LSD)·Attention-deficit/hyperactivity disorderPhase 2Phase 2a proof-of-concept ADHD study (NCT05200936 / MMED007) completed (study completion date 2023-12-04; primary completion 2023-11-06).source ↗
Trials recruiting · 2 recruiting of 6 sponsored
Phase 3 Study of MM120 (Lysergide) in Major Depressive Disorder (Emerge)
- Phase 2DT402
An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder
Competitive landscape
Other companies developing against Definium Therapeutics, Inc.'s targets or indications.
- Otsuka Pharmaceutical Co., Ltd.4 compoundsSERTGeneralized anxiety disorderMajor depressive disorderPost-traumatic stress disorderAttention-deficit/hyperactivity disorder
- Intra-Cellular Therapies, Inc.2 compounds5-HT2AAutism spectrum disorderGeneralized anxiety disorderMajor depressive disorder
- COMPASS Pathways plc1 compound5-HT2AMajor depressive disorderPost-traumatic stress disorder
- Helus Pharma2 compounds5-HT2AGeneralized anxiety disorderMajor depressive disorder
- Axsome Therapeutics, Inc.1 compoundMajor depressive disorderAttention-deficit/hyperactivity disorder
- Beckley Psytech Limited1 compound5-HT2AMajor depressive disorder
- Delix Therapeutics, Inc.1 compound5-HT2AMajor depressive disorder
- Gilgamesh Pharmaceuticals, Inc.2 compounds5-HT2AMajor depressive disorder
- Mindset Pharma Inc.1 compound5-HT2AMajor depressive disorder
- Reunion Neuroscience Inc.1 compound5-HT2AGeneralized anxiety disorder
- Tonix Pharmaceuticals Holding Corp.1 compoundMajor depressive disorderPost-traumatic stress disorder
- Transcend Therapeutics, Inc.1 compoundSERTPost-traumatic stress disorder
